More than half of chemotherapy patients develop peripheral neuropathy, and duloxetine remains the only drug with meaningful clinical evidence behind it, prescribed off-label with no regulatory approval specifically for the condition. Against that backdrop, MIRA Pharmaceuticals disclosed September 17 that its Phase 2a program evaluating Ketamir-2, an oral NMDA receptor modulator, has moved toward site initiation after the FDA completed its review of the study protocol. That sequence matters: the FDA cleared Ketamir-2’s IND for neuropathic pain in July 2025, the Phase 1 read was positive in May 2026, and a Phase 2a in chemotherapy-induced peripheral neuropathy (CIPN) is now actively opening sites, all within roughly 14 months.
The Phase 1 trial enrolled 57 healthy volunteers in single and multiple ascending dose cohorts, producing data MIRA described as positive on safety, tolerability, and pharmacokinetics. That controlled, blinded study design is a reasonable foundation for the CIPN program, though Phase 1 data in healthy volunteers says nothing about efficacy in patients whose neuropathy stems from neurotoxic chemotherapy agents. The Phase 2a will need to answer whether the receptor-level activity translates into measurable pain or functional relief in that population.
CIPN is a practical target for a first efficacy trial. Meta-analyses put incidence around 56% across treated cancer patients, with rates reaching 90% in patients receiving the most neurotoxic regimens. The patient pool is large, the condition is chronic and undertreated, and approved options remain limited, which makes enrollment messaging and physician interest less of a barrier than in crowded indications. For a small-cap company running a lean clinical program, that access is not trivial.
The disclosure came via an 8-K Regulation FD filing, which means MIRA’s obligation was to release material information simultaneously to all investors rather than to report a formal milestone. Site initiation is a process, not a single date, so the immediate marker to track is when the company discloses first-patient enrollment in the Phase 2a, which will confirm that the protocol review translated into an active, accruing trial.
Source link: https://www.sec.gov/Archives/edgar/data/1904286/000149315226043051/form8-k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
